Anthera Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016
February 27, 2017 at 05:00 pm
Share
Anthera Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported total revenues of $0 against $1,918,000 a year ago. Loss from operations was $14,579,000 against $7,390,000 a year ago. Net loss applicable to common stockholders was $15,092,000 or $0.36 basic and diluted per share against $7,339,000 or $0.18 basic and diluted per share a year ago. The increase in net loss is mainly attributable to the increase in manufacturing expense for Sollpura™ and clinical study expense for both Sollpura™ and blisibimod in 2016.
For the year, the company reported total revenues of $145,000 against $3,185,000 a year ago.
Loss from operations was $57,177,000 against $35,243,000 a year ago. Net loss applicable to common stockholders was $66,437,000 or $1.61 basic and diluted per share against $35,220,000 or $0.99 basic and diluted per share a year ago. The increase in net loss is mainly attributable to the increase in manufacturing expense for Sollpura™ and clinical study expense for both Sollpura™ and blisibimod in 2016.
Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.